Lisanti Capital Growth’s Abiomed Inc ABMD Stock Holding History

Lisanti Capital Growth’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-3,490	Closed	-$1.43M	–	162
2018 Q2	$1.43M	Sell	3,490 -1,480	-30%	-$536K	0.55%	78
2018 Q1	$1.45M	Buy	4,970 +1,520	+44%	+$385K	0.7%	66
2017 Q4	$647K	Sell	3,450 -45	-1%	-$8.4K	0.37%	94
2017 Q3	$589K	Buy	3,495 +770	+28%	+$116K	0.37%	91
2017 Q2	$390K	Buy	+2,725	New	+$366K	0.26%	106
2016 Q3	–	Sell	-4,675	Closed	-$511K	–	115
2016 Q2	$511K	Buy	4,675 +1,945	+71%	+$194K	0.77%	62
2016 Q1	$259K	Buy	+2,730	New	+$230K	0.31%	96
2015 Q4	–	Sell	-21,389	Closed	-$1.98M	–	109
2015 Q3	$1.98M	Buy	21,389 +3,724	+21%	+$328K	1.79%	13
2015 Q2	$1.16M	Buy	+17,665	New	+$1.17M	0.84%	64

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Lisanti Capital Growth's ABMD Position: Q3 2018 in Review

Lisanti Capital Growth sold out of Abiomed Inc (ABMD) in Q3 2018, closing a stake of 3,490 shares — an estimated $1.43M sold.

Lisanti Capital Growth first reported a position in ABMD in Q2 2015 and held it in 9 quarters. The position peaked at $1.98M in Q3 2015. 529 funds tracked by Wall St. Rank hold ABMD as of Q3 2018.

Lisanti Capital Growth reported no remaining Abiomed Inc position as of Q3 2018 after selling out during the quarter.
Lisanti Capital Growth sold 3,490 Abiomed Inc shares in Q3 2018, an estimated $1.43M.
Lisanti Capital Growth first reported a position in Abiomed Inc in Q2 2015 and held it in 9 quarters.
Lisanti Capital Growth's Abiomed Inc position peaked at $1.98M in Q3 2015.
529 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2018.

Based on Lisanti Capital Growth's 13F filing for Q3 2018, filed 5 Nov 2018.